预防研究
ENGLISH ABSTRACT
不同年龄下总前列腺特异性抗原和游离/总前列腺特异性抗原比值筛查前列腺癌的最佳切点值探讨及验证
刘晓敏
段洪媛
张东琦
陈冲
吉雨婷
张芸萌
冯卓伟
刘亚
李净净
张钰
李晨阳
张雅聪
杨雷
吕章艳
宋方方
宋丰举
黄育北
作者及单位信息
·
DOI: 10.3760/cma.j.cn112152-20230805-00062
Exploration and validation of optimal cut-off values for tPSA and fPSA/tPSA screening of prostate cancer at different ages
Liu Xiaomin
Duan Hongyuan
Zhang Dongqi
Chen Chong
Ji Yuting
Zhang Yunmeng
Feng Zhuowei
Liu Ya
Li Jingjing
Zhang Yu
Li Chenyang
Zhang Yacong
Yang Lei
Lyu Zhangyan
Song Fangfang
Song Fengju
Huang Yubei
Authors Info & Affiliations
Liu Xiaomin
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Duan Hongyuan
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Zhang Dongqi
Department of Hospital Information System, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Chen Chong
Department of Clinical Laboratory, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Ji Yuting
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Zhang Yunmeng
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Feng Zhuowei
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Liu Ya
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Li Jingjing
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Zhang Yu
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Li Chenyang
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Zhang Yacong
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Yang Lei
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital & Institute, Beijing 100143, China
Lyu Zhangyan
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Song Fangfang
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Song Fengju
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Huang Yubei
Department of Cancer Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
·
DOI: 10.3760/cma.j.cn112152-20230805-00062
663
146
0
0
3
0
PDF下载
APP内阅读
摘要

目的探讨总人群及不同年龄下总前列腺特异性抗原(tPSA)和游离前列腺特异性抗原(fPSA)与tPSA比值(fPSA/tPSA)筛查前列腺癌的最佳切点值及筛查准确性。

方法基于天津市常见恶性肿瘤联合筛查项目人群及同期天津市常见恶性肿瘤队列人群,选取2017年以来基线未患癌且接受tPSA及fPSA检测的男性,基于Cox回归采用时间依赖的受试者工作特征曲线(tdROC)及曲线下面积(tdAUC)评价tPSA和fPSA/tPSA比值筛查2年内总体人群及年龄特异性(<60岁、60~<70岁及≥70岁)新发前列腺癌的准确性及最佳切点值。采用Bootstrap重抽样内部验证最佳切点值的稳定性,并采用前列腺、肺、结肠和卵巢癌筛查试验(PLCO)人群外部验证不同切点值下的筛查准确性。

结果共5 180名参与者纳入研究,中位随访1.48年后,共发现332例前列腺癌患者。总人群中( n=5 180),tPSA和fPSA/tPSA筛查2年内新发前列腺癌的tdAUC分别为0.852和0.748,最佳切点值分别为5.08 ng/ml和0.173。按年龄分层后,<60岁、60~<70岁和≥70岁年龄组tPSA年龄特异性切点值分别为3.13、4.82、11.54 ng/ml,年龄别特异性fPSA/tPSA最佳切点值分别为0.153、0.135、0.130。相应年龄别特异性切点值下,<60岁、60~<70岁和≥70岁男性tPSA筛查前列腺癌的灵敏度分别为92.3%、82.0%和77.6%,特异度分别为84.7%、81.3%和75.4%;fPSA/tPSA 筛查前列腺癌的灵敏度分别为74.4%、53.3%和55.9%,特异度分别为83.8%、83.7%和83.7%。Bootstrap内部验证及PLCO外部验证均得到类似的结果,tPSA及fPSA/tPSA联合后可进一步改善筛查的准确性。

结论为提高筛查准确性,推荐在一般风险人群中,采用年龄别特异性的tPSA和fPSA/tPSA筛查切点值来筛查前列腺癌。

前列腺肿瘤;总前列腺特异性抗原;游离前列腺特异性抗原;筛查;年龄特异性筛查切点值
ABSTRACT

ObjectiveTo determine the total and age-specific cut-off values of total prostate specific antigen (tPSA) and the ratio of free PSA divided total PSA (fPSA/tPSA) for screening prostate cancer in China.

MethodsBased on the Chinese Colorectal, Breast, Lung, Liver, and Stomach cancer Screening Trial (C-BLAST) and the Tianjin Common Cancer Case Cohort (TJ4C), males who were not diagnosed with any cancers at baseline since 2017 and received both tPSA and fPSA testes were selected. Based on Cox regression, the overall and age-specific (<60, 60-<70, and ≥70 years) accuracy and optimal cut-off values of tPSA and fPSA/tPSA ratio for screening prostate cancer were evaluated with time-dependent receiver operating characteristic curve (tdROC) and area under curve (AUC). Bootstrap resampling was used to internally validate the stability of the optimal cut-off value, and the PLCO study was used to externally validate the accuracy under different cut-off values.

ResultsA total of 5 180 participants were included in the study, and after a median follow-up of 1.48 years, a total of 332 prostate cancer patients were included. In the total population, the tdAUC of tPSA and fPSA/tPSA screening for prostate cancer were 0.852 and 0.748, respectively, with the optimal cut-off values of 5.08 ng/ml and 0.173, respectively. After age stratification, the age specific cut-off values of tPSA in the <60, 60-<70, and ≥70 age groups were 3.13, 4.82, and 11.54 ng/ml, respectively, while the age-specific cut-off values of fPSA/tPSA were 0.153, 0.135, and 0.130, respectively. Under the age-specific cut-off values, the sensitivities of tPSA screening for prostate cancer in males <60, 60-70, and ≥70 years old were 92.3%, 82.0%, and 77.6%, respectively, while the specificities were 84.7%, 81.3%, and 75.4%, respectively. The age-specific sensitivities of fPSA/tPSA for screening prostate cancer were 74.4%, 53.3%, and 55.9%, respectively, while the specificities were 83.8%, 83.7%, and 83.7%, respectively. Both bootstrap's internal validation and PLCO external validation provided similar results. The combination of tPSA and fPSA/tPSA could further improve the accuracy of screening.

ConclusionTo improve the screening effects, it is recommended that age-specific cut-off values of tPSA and fPSA/tPSA should be used to screen for prostate cancer in the general risk population.

Prostate neoplasms;tPSA;fPSA;Screening;Age-specific screening cut-off values
Huang Yubei, Email: mocdef.3ab61gnauh_iebuy
引用本文

刘晓敏,段洪媛,张东琦,等. 不同年龄下总前列腺特异性抗原和游离/总前列腺特异性抗原比值筛查前列腺癌的最佳切点值探讨及验证[J]. 中华肿瘤杂志,2024,46(04):354-364.

DOI:10.3760/cma.j.cn112152-20230805-00062

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
前列腺癌是全球男性第2常见的恶性肿瘤(仅次于肺癌),2020年全球前列腺癌新发141万例,死亡37万例 1。2020年,前列腺癌在中国男性恶性肿瘤发病中排名第6位,且近年来其发病率呈明显上升的趋势 2 , 3 , 4。由于前列腺癌症状比较隐蔽,诊断时患者大多已处于晚期或并发多处转移 5,因此早期发现并诊断前列腺癌对于改善前列腺癌患者的预后和减少死亡尤为重要。为了减轻前列腺癌疾病负担,早在几十年前西方国家就已经将前列腺特异性抗原(prostate-specific antigen,PSA)作为前列腺癌的主要筛查方法之一。目前已有大型随机对照试验证实PSA筛查能显著降低前列腺癌死亡。如欧洲前列腺癌筛查随机研究显示,PSA筛查可显著降低50~74岁男性20%的前列腺癌死亡率 6;PROBASE研究表明,PSA筛查可抑制前列腺癌向转移性疾病进展,且45岁男性中侵袭性前列腺癌的检出率非常低 7。但是,也有研究显示,PSA筛查并不能降低前列腺癌的死亡率,如英国前列腺癌PSA检测的整群随机试验和美国前列腺、肺、结肠和卵巢癌筛查试验(the prostate,lung,colorectal and ovarian cancer screening trial,PLCO) 8 , 9 , 10。造成上述研究结果不一致的原因可能有很多,其中包括PSA筛查前列腺癌的特异度较低,即PSA异常升高也见于其他良性前列腺疾病 11,从而造成假阳性。同时前列腺癌相比肝癌、肺癌、结直肠癌等其他常见恶性肿瘤进展速度相对较慢,容易造成过度诊断和过度治疗 12 , 13。因此,如何提高PSA筛查效果,成为前列腺癌筛查领域的关键问题之一。
为了改善PSA的筛查效果,不少研究对PSA衍生物的筛查效果进行了探讨,比如游离前列腺特异性抗原(free prostate specific antigen,fPSA)和fPSA/总前列腺特异性抗原(total prostate specific antigen,tPSA)比值。PSA进入血液中大部分与蛋白结合,少部分呈游离状态称为fPSA。研究表明,fPSA/tPSA可以改善PSA对前列腺癌的筛查效果,减少不必要的活检 14 , 15。尤其是在PSA浓度在2~20 ng/ml范围内时,单项的tPSA不能明确鉴别前列腺癌和良性前列腺增生,因为两者有交叉;而fPSA/tPSA比值在前列腺癌患者中明显偏低,在良性前列腺增生患者中显著增高,因此,在tPSA基础上,通过fPSA/tPSA比值可达到鉴别前列腺癌或良性前列腺增生的目的 16。因此联合2个指标,可进一步改善对前列腺癌的筛查效果。同时,许多研究提出针对不同年龄的男性采用相同的PSA切点值筛查前列腺癌,很可能是影响PSA筛查效果的重要原因之一。已有研究显示,PSA与年龄存在明显的相关性,随着年龄的增加,PSA水平也随之升高 17 , 18,同时已有研究对年龄特异性PSA筛查切点值也进行了探讨 19 , 20。然而这些研究多来源于前列腺癌高发的欧美人群,由于种族差异 21,上述研究结果很可能并不适用于中国人群。
我国开展的以人群为基础的PSA筛查较少,在我国长春市进行的前列腺癌筛查是我国开展的第1个前列腺癌筛查研究,该研究显示,PSA筛查可以提高早期癌的检出率,并且随着年龄的增长,前列腺癌的发病率也逐渐升高 22。在兰州和扬州地区进行的PSA筛查也发现了类似结果 23 , 24,然而对于年龄特异性的PSA切点值尚缺乏探讨。此外,中国人群中很少有研究探讨fPSA/tPSA比值筛查前列腺癌的准确性,更少有研究探讨不同年龄下该指标筛查前列腺癌的最佳切点值和准确性。因此,本研究的主要目的是探讨在中国男性一般风险人群中,分别采用tPSA和fPSA/tPSA比值筛查前列腺癌的效果,以及探讨总人群及不同年龄别亚组人群中,tPSA和fPSA/tPSA筛查前列腺癌的最佳切点值,以改善前列腺癌的筛查效果,并为我国前列腺癌筛查实践提供证据支持。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Siegel RL , Miller KD , Fuchs HE ,et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022,72(1):7-33. DOI: 10.3322/caac.21708 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Sung H , Ferlay J , Siegel RL ,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249. DOI: 10.3322/caac.21660 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Chen WQ , Zheng RS , Baade PD ,et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组. 前列腺癌筛查中国专家共识(2021年版)[J]. 中国癌症杂志, 2021,31(5):435-440. DOI: 10.19401/j.cnki.1007-3639.2021.05.010 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
马春光,叶定伟,李长岭,. 前列腺癌的流行病学特征及晚期一线内分泌治疗分析[J]. 中华外科杂志, 2008,46(12):921-925. DOI: 10.3321/j.issn:0529-5815.2008.12.012 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Hugosson J , Roobol MJ , Månsson M ,et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer[J]. Eur Urol, 2019,76(1):43-51. DOI: 10.1016/j.eururo.2019.02.009 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Arsov C , Becker N , Hadaschik BA ,et al. Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial[J]. Eur Urol, 2013,64(6):873-875. DOI: 10.1016/j.eururo.2013.05.022 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Andriole GL , Crawford ED , Grubb RL ,et al. Mortality results from a randomized prostate-cancer screening trial[J]. N Engl J Med, 2009,360(13):1310-1319. DOI: 10.1056/NEJMoa0810696 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Pinsky PF , Prorok PC , Yu K ,et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years[J]. Cancer, 2017,123(4):592-599. DOI: 10.1002/cncr.30474 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Martin RM , Donovan JL , Turner EL ,et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial[J]. JAMA, 2018,319(9):883-895. DOI: 10.1001/jama.2018.0154 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Stamey TA , Yang N , Hay AR ,et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate[J]. N Engl J Med, 1987,317(15):909-916. DOI: 10.1056/NEJM198710083171501 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Welch HG , Albertsen PC . Reconsidering prostate cancer mortality - the future of PSA screening[J]. N Engl J Med, 2020,382(16):1557-1563. DOI: 10.1056/NEJMms1914228 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Wittmann D , Skolarus T , Glodé LM . Reconsidering the trade-offs of prostate cancer screening[J]. N Engl J Med, 2020,383(13):1289-1290. DOI: 10.1056/NEJMc2025138 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Catalona WJ , Smith DS , Wolfert RL ,et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening[J]. JAMA, 1995,274(15):1214-1220.
返回引文位置Google Scholar
百度学术
万方数据
[15]
Vashi AR , Oesterling JE . Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer[J]. Mayo Clin Proc, 1997,72(4):337-344. DOI: 10.4065/72.4.337 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Catalona WJ , Smith DS , Ornstein DK . Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements[J]. JAMA, 1997,277(18):1452-1455.
返回引文位置Google Scholar
百度学术
万方数据
[17]
Babaian RJ , Miyashita H , Evans RB ,et al. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age[J]. J Urol, 1992,147(3Pt 2):837-840. DOI: 10.1016/s0022-5347(17)37400-1 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
王功伟,沈丹华. 前列腺腺癌患者年龄与血清PSA相关性初步分析[J]. 现代泌尿生殖肿瘤杂志, 2014,6(3):146-149. DOI: 10.3870/j.issn.1674-4624.2014.03.006 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Oesterling JE , Jacobsen SJ , Chute CG ,et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges[J]. JAMA, 1993,270(7):860-864.
返回引文位置Google Scholar
百度学术
万方数据
[20]
National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment (February 2008)[EB/OL]. [ 2024-01-20]. https://www.nice.org.uk/guidance/CG58.
返回引文位置Google Scholar
百度学术
万方数据
[21]
DeAntoni EP , Crawford ED , Oesterling JE ,et al. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study[J]. Urology, 1996,48(2):234-239. DOI: 10.1016/s0090-4295(96)00091-x .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Li XM , Tsuji I , Kuwahara M ,et al. Mass screening of prostate cancer in Changchun city of China[J]. Int Urol Nephrol, 2004,36(4):541-548. DOI: 10.1007/s11255-004-0842-0 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
殷桂草,田浩宇,田锋,. 以PSA筛查为基础前列腺癌早期诊断与治疗的研究[J]. 蚌埠医学院学报, 2023,48(4):441-444. DOI: 10.13898/j.cnki.issn.1000-2200.2023.04.005 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
李绪,李荣欣,关心,. 兰州地区目标人群前列腺癌筛查及异常PSA值影响因素分析[J]. 中国男科学杂志, 2022,36(3):3-13. DOI: 10.3969/j.issn.1008-0848.2022.03.001 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Du YH , Zhao YR , Sidorenkov G ,et al. Methods of computed tomography screening and management of lung cancer in Tianjin: design of a population-based cohort study[J]. Cancer Biol Med, 2019,16(1):181-188. DOI: 10.20892/j.issn.2095-3941.2018.0237 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Sheng C , Sun LP , Lyu ZY ,et al. Development of a modified ABC method among Helicobacter pylori infected but serum pepsinogen test-negative individuals[J]. Helicobacter, 2023,28(3):e12966. DOI: 10.1111/hel.12966 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Huang YB , Lyu ZY , Zhang Y ,et al. Cohort profile: design and methods of the Chinese colorectal, breast, lung, liver, and stomach cancer screening trial (C-BLAST)[J]. Cancer Biol Med, 2023,20(10):713-720. DOI: 10.20892/j.issn.2095-3941.2023.0278 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Li JX , Li CY , Feng ZW ,et al. Effect of estradiol as a continuous variable on breast cancer survival by menopausal status: a cohort study in China[J]. Breast Cancer Res Treat, 2022,194(1):103-111. DOI: 10.1007/s10549-022-06593-5 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Li JX , Liu LY , Feng ZW ,et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study[J]. Breast Cancer, 2020,27(4):621-630. DOI: 10.1007/s12282-020-01058-3 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Zhang LW , Huang YB , Feng ZW ,et al. Comparison of breast cancer risk factors among molecular subtypes: a case-only study[J]. Cancer Med, 2019,8(4):1882-1892. DOI: 10.1002/cam4.2012 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
Gohagan JK , Prorok PC , Hayes RB ,et al. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the national cancer institute: history, organization, and status[J]. Control Clin Trials, 2000,21(Suppl 6):251S-272S. DOI: 10.1016/s0197-2456(00)00097-0 .
返回引文位置Google Scholar
百度学术
万方数据
[32]
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)前列腺癌诊疗指南2022[M]. 北京:人民卫生出版社, 2022.
[33]
Schröder FH , Hugosson J , Roobol MJ ,et al. Prostate-cancer mortality at 11 years of follow-up[J]. N Engl J Med, 2012,366(11):981-990. DOI: 10.1056/NEJMoa1113135 .
返回引文位置Google Scholar
百度学术
万方数据
[34]
Draisma G , Etzioni R , Tsodikov A ,et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context[J]. J Natl Cancer Inst, 2009,101(6):374-383. DOI: 10.1093/jnci/djp001 .
返回引文位置Google Scholar
百度学术
万方数据
[35]
Lankford SP , Peters KL , Elser RC . Potential effects of age-specific reference ranges for serum prostate-specific antigen[J]. Eur Urol, 1995,27(3):182-186. DOI: 10.1159/000475157 .
返回引文位置Google Scholar
百度学术
万方数据
[36]
Matti B , Zargar-Shoshtari K . Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population[J]. Int J Urol, 2021,28(5):578-583. DOI: 10.1111/iju.14519 .
返回引文位置Google Scholar
百度学术
万方数据
[37]
Carter HB , Pearson JD , Metter EJ ,et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease[J]. JAMA, 1992,267(16):2215-2220.
返回引文位置Google Scholar
百度学术
万方数据
[38]
Martin BJ , Finlay JA , Sterling K ,et al. Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA)[J]. Prostate Cancer Prostatic Dis, 2004,7(2):132-137. DOI: 10.1038/sj.pcan.4500706 .
返回引文位置Google Scholar
百度学术
万方数据
[39]
Toubert ME , Guillet J , Chiron M ,et al. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer[J]. Eur J Cancer, 1996,32A(12):2088-2093. DOI: 10.1016/s0959-8049(96)00245-6 .
返回引文位置Google Scholar
百度学术
万方数据
[40]
Mungan AG , Erol B , Akduman B ,et al. Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population[J]. Clin Chem Lab Med, 2007,45(7):912-916. DOI: 10.1515/CCLM.2007.501 .
返回引文位置Google Scholar
百度学术
万方数据
[41]
Chen R , Huang YR , Cai XB ,et al. Age-specific cutoff value for the application of percent free prostate-specific antigen (PSA) in Chinese men with serum PSA levels of 4.0-10.0 ng/ml[J]. PLoS One, 2015,10(6):e0130308. DOI: 10.1371/journal.pone.0130308 .
返回引文位置Google Scholar
百度学术
万方数据
[42]
Mucci LA , Hjelmborg JB , Harris JR ,et al. Familial risk and heritability of cancer among twins in Nordic countries[J]. JAMA, 2016,315(1):68-76. DOI: 10.1001/jama.2015.17703 .
返回引文位置Google Scholar
百度学术
万方数据
[43]
Nordström T , Discacciati A , Bergman M ,et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial[J]. Lancet Oncol, 2021,22(9):1240-1249. DOI: 10.1016/S1470-2045(21)00348-X .
返回引文位置Google Scholar
百度学术
万方数据
[44]
Eklund M , Jäderling F , Discacciati A ,et al. MRI-targeted or standard biopsy in prostate cancer screening[J]. N Engl J Med, 2021,385(10):908-920. DOI: 10.1056/NEJMoa2100852 .
返回引文位置Google Scholar
百度学术
万方数据
[45]
Lee F , Littrup PJ , Loft-Christensen L ,et al. Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer[J]. Cancer, 1992,70(Suppl 1):211-220. DOI: 10.1002/1097-0142(19920701)70:1+<211::aid-cncr2820701307>3.0.co;2-d .
返回引文位置Google Scholar
百度学术
万方数据
[46]
Grönberg H , Adolfsson J , Aly M ,et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study[J]. Lancet Oncol, 2015,16(16):1667-1676. DOI: 10.1016/S1470-2045(15)00361-7 .
返回引文位置Google Scholar
百度学术
万方数据
[47]
Parekh DJ , Punnen S , Sjoberg DD ,et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer[J]. Eur Urol, 2015,68(3):464-470. DOI: 10.1016/j.eururo.2014.10.021 .
返回引文位置Google Scholar
百度学术
万方数据
[48]
Ström P , Nordström T , Aly M ,et al. The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential[J]. Eur Urol, 2018,74(2):204-210. DOI: 10.1016/j.eururo.2017.12.028 .
返回引文位置Google Scholar
百度学术
万方数据
[49]
Gentile F , La Civita E , Della Ventura B ,et al. A combinatorial neural network analysis reveals a synergistic behaviour of multiparametric magnetic resonance and prostate health index in the identification of clinically significant prostate cancer[J]. Clin Genitourin Cancer, 2022,20(5):e406-e410. DOI: 10.1016/j.clgc.2022.04.013 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
黄育北,Email: mocdef.3ab61gnauh_iebuy
B

刘晓敏、段洪媛:数据收集、文献检索、论文撰写;刘晓敏、段洪媛、张东琦、陈冲、吉雨婷、张芸萌、冯卓伟、刘亚、李净净、张钰、李晨阳、张雅聪:数据整理、统计学分析、论文修改;黄育北、杨雷、吕章艳、宋方方、宋丰举:研究指导、论文修改、经费支持

C
刘晓敏, 段洪媛, 张东琦, 等. 不同年龄下总前列腺特异性抗原和游离/总前列腺特异性抗原比值筛查前列腺癌的最佳切点值探讨及验证[J]. 中华肿瘤杂志, 2024, 46(4): 354-364. DOI: 10.3760/cma.j.cn112152-20230805-00062.
D
所有作者声明无利益冲突
E
国家重点研发项目 (2021YFC2500400,2018YFC1315600)
天津市卫生健康委员会项目 (TJWJ2021MS008)
天津市医学重点学科(专科)建设项目 (TYXZDXK-009A)
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号